Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models

In combination cancer immunotherapies, consideration should be given to designing treatment schedules that harmonize with the immune system’s natural timing. An efficacious temporally programmed combination therapy of extended half-life interleukin 2 (eIL2), tumor targeting antibody, and interferon...

Full description

Bibliographic Details
Main Authors: Adrienne Rothschilds, Alice Tzeng, Naveen K. Mehta, Kelly D. Moynihan, Darrell J. Irvine, K. Dane Wittrup
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1558678